Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 13/20 | 0.54 |
| ▸ | GABRG2 | P18507 | 10/20 | 0.54 |
| ▸ | GABRB3 | P28472 | 10/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30282901 | 1.00 | GABRA5 (0.54) | GABRA5GABRG2GABRB3KCNH2PTGS2 | |
| SCHEMBL25045396 | 0.90 | GABRA5 (0.44) | GABRA5GABRG2GABRB3KCNH2PTGS2 | |
| SCHEMBL25044752 | 0.90 | GABRA5 (0.44) | GABRA5GABRG2GABRB3KCNH2ALDH1A1 | |
| SCHEMBL25045401 | 0.88 | GABRA5 (0.43) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL30283019 | 0.88 | GABRA5 (0.43) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL30236918 | 0.88 | GABRA5 (0.41) | GABRA5GABRG2GABRB3KCNH2ALDH1A1 | |
| SCHEMBL25045281 | 0.88 | GABRA5 (0.41) | GABRA5GABRG2GABRB3KCNH2ALDH1A1 | |
| SCHEMBL21623964 | 0.87 | GABRA5 (0.43) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL25044792 | 0.87 | GABRA5 (0.43) | GABRA5GABRG2GABRB3KCNH2 | |
| SCHEMBL30282856 | 0.87 | GABRA5 (0.43) | GABRA5GABRG2GABRB3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | claimed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | claimed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | claimed |
| CN-103221402-A | Triazole derivatives and their use for neurological disorders | HOFFMANN LA ROCHE | 2013-07-24 | — | — | CN | claimed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | claimed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | claimed |
| CN-115703765-A | Substituted triazole derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| WO-2023016521-A1 | SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| EP-2638029-B1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-09-24 | — | — | EP | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8742097-B2 | Triazole compounds I | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2638029-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| CN-103221402-A | Triazole derivatives and their use for neurological disorders | HOFFMANN LA ROCHE | 2013-07-24 | — | — | CN | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062687-A1 | TRIAZOLE DERIVATIVES AND THEIR USE FOR NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | ROCHE PALO ALTO LLC | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115844-A1 | NOVEL TRIAZOLE COMPOUNDS I | GABRA5, GABRA3, GABRA1 | GABRA5 1/4885GABRG2 28/4885GABRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.